Onyx's (ONXX) Myeloma Drug Might be used for Earlier Stage Treatments

Article Stock Quotes (1) Comments (0)

Dr. Ravi Vij, associate professor at the department of Medicine at Washington University, told analyst Ling Wang of Summer Street that Kyprolis may eventually be used in the majority of his 3rd-line or higher patients. He is also hoping to use it in 2nd-line patients, assuming he doesn’t get pushback on reimbursement.

Vij doesn’t expect higher dose Kyprolis front-line use before official approval, but he has treated a dozen patients with Kyprolis over past two weeks. Initial patients treated tend to be heavily pretreated, 4th or 5th line patients.

Shares of Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) are higher by 70 percent year-to-day.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• BlackBerry (BBRY) Q10 Sales 'Strong' in Canada, Won't Help If U.S. Flops
• Deutsche Bank Downgrades Signet Jewelers (SIG) to Hold
• Dover (DOV) Latest Diversified Industrial to Announce Streamlining; More to Follow?

Create E-mail Alert Related Categories

Analyst Comments, General News

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?